Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

hives

- PMLiVE

InflaRx reports positive phase 2 results for HS and CSU treatments

Topline results demonstrated treatment efficacy for both conditions

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

- PMLiVE

Novartis reveals positive efficacy data for Xolair follow-up

Next-generation treatment is more effective than current therapy

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

Novartis building

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Novartis building

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links